The enhancement of PI3K-Akt and EGFR signalling pathways, recognised as key contributors to CCA progression, further emphasises the potential of medicarpin as a multi-target treatment candidate for this cancer. This evidence concerns the gene AKT1 and cholangiocarcinoma.